Physicians must, therefore, take into account both the gastrointestinal and the cardiovascular risks of individual patients when prescribing NSAIDs. In patients with a low cardiovascular risk ...

Naproxcinod [(S)-2-(6-Methoxy-2-naphthyl)propanoic acid 4-nitrooxybutyl ester], that is, NO-naproxen, is the first of the class of cyclooxygenase-inhibiting NO donators, and is currently in Phase ...

NEW YORK, June 19 (Praxis Press) Non-steroidal anti-inflammatory drugs (NSAIDs ... drugs on the risk of developing common cancers (see paper). The study group consisted of patients taking NSAIDs who ...

These drugs can bother the GI tract in a number of different ... other medical problems are at especially increased risk. "If you're taking NSAIDs on a chronic basis, there's a very high ...